India-Manufactured Bundibugyo Ebola Vaccine Candidate Enters a Phase I Study in Uganda
A Uganda study will test safety and immune responses to Oxford’s investigational Bundibugyo Ebola vaccine, manufactured by Serum Institute of India. This is an early clinical milestone, not proof of protection.
An Ebola vaccine candidate manufactured in India has reached a new clinical setting. Uganda has begun a Phase I study of Oxford’s ChAdOx-based Bundibugyo virus vaccine, Serum Institute of India reported on 7 October 2026. The release places the first vaccinations in Masaka on 5 October.
The MRC/UVRI & LSHTM Uganda Research Unit is evaluating safety and immune responses in healthy adults, with the University of Oxford sponsoring the study and CEPI funding it. This follows an earlier UK Phase I trial, covered by DeepTech India in July.
India's contribution is manufacturing
Oxford developed the candidate. Serum Institute says it manufactured and stockpiled approximately 620,000 investigational doses in two weeks and supplied about 3,000 doses for the Uganda trial. These are attributed manufacturing figures, not evidence that the vaccine has been licensed or that stockpiled doses have been administered.
What the trial can establish
The key distinction is between generating an immune response and demonstrating protection against disease. This announcement reports a study launch, with no safety or efficacy results. Late-stage trials remain conditional on early-stage findings, according to the release.
That makes the Uganda study relevant beyond the production headline. A manufacturing reserve may shorten the time needed to supply subsequent studies, but it cannot substitute for clinical evidence. Safety monitoring, the strength and durability of immune responses, and the design of any subsequent efficacy study will determine the candidate’s development path.
The Indian role here is therefore specific: producing an investigational biological product for international clinical research. The next meaningful update should be trial data or a clearly defined next phase, rather than another count of doses made.